Title: | Pioglitazone improves whole-body aerobic capacity and skeletal muscle energy metabolism in patients with metabolic syndrome |
Authors: | Yokota, Takashi Browse this author →KAKEN DB |
Kinugawa, Shintaro Browse this author →KAKEN DB |
Hirabayashi, Kagami Browse this author |
Suga, Tadashi Browse this author →KAKEN DB |
Takada, Shingo Browse this author →KAKEN DB |
Omokawa, Masashi Browse this author |
Kadoguchi, Tomoyasu Browse this author |
Takahashi, Masashige Browse this author |
Fukushima, Arata Browse this author →KAKEN DB |
Matsushima, Shouji Browse this author |
Yamato, Mayumi Browse this author →KAKEN DB |
Okita, Koichi Browse this author →KAKEN DB |
Tsutsui, Hiroyuki Browse this author →KAKEN DB |
Keywords: | Clinical |
Metabolic syndrome |
Treatment drug |
Issue Date: | Jul-2017 |
Publisher: | John Wiley & Sons |
Journal Title: | Journal of Diabetes Investigation |
Volume: | 8 |
Issue: | 4 |
Start Page: | 535 |
End Page: | 541 |
Publisher DOI: | 10.1111/jdi.12606 |
Abstract: | Aims/Introduction: Low aerobic capacity is a strong and independent predictor of all-cause mortality in patients with metabolic syndrome (MetS). Here, we investigated the effects of pioglitazone treatment on whole-body aerobic capacity and skeletal muscle energy metabolism in MetS patients. Materials and Methods: A total of 14 male patients with MetS received oral pioglitazone 15 mg/day for 4 months. To assess whole-body aerobic capacity, exercise testing with a bicycle ergometer was carried out before and after pioglitazone treatment. To assess skeletal muscle energy metabolism, intramyocellular lipid in the resting leg and high-energy phosphates in the calf muscle during plantar-flexion exercise were measured using 1proton- and 31phosphorus magnetic resonance spectroscopy, respectively. Results: Pioglitazone significantly increased peak oxygen uptake (25.1 ± 4.9 mL/kg/min pretreatment vs 27.2 ± 3.9 mL/kg/min post- treatment, P < 0.05) and anaerobic threshold (12.7 ± 1.9 mL/kg/min pretreatment vs 13.6 ± 1.6 mL/kg/min post-treatment, P < 0.05), although daily physical activity was comparable before and after the treatment. Intramyocellular lipid content was significantly reduced after pioglitazone treatment by 26%, indicating improved skeletal muscle fatty acid metabolism. Pioglitazone also significantly decreased the muscle phosphocreatine loss during exercise by 13%, indicating improved skeletal muscle high-energy phosphate metabolism. Notably, the increase in anaerobic threshold; that is, submaximal aerobic capacity, closely correlated with the decrease in intramyocellular lipid content after pioglitazone treatment. Conclusions: Pioglitazone significantly improved the MetS patients' whole-body aerobic capacity and skeletal muscle energy metabolism. The beneficial effect of pioglitazone on whole-body aerobic capacity might be at least in part through improved fatty acid metabolism in the skeletal muscle. |
Rights: | https://creativecommons.org/licenses/by-nc/4.0/ |
Type: | article |
URI: | http://hdl.handle.net/2115/67069 |
Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|